PHASE-II TRIAL OF TRIMELAMOL IN REFRACTORY OVARIAN-CANCER

被引：8

作者：

JUDSON, IR

CALVERT, AH

GORE, ME

BALMANNO, K

GUMBRELL, LA

PERREN, T

WILTSHAW, E

机构：

[1] INST CANC RES,MED SECT,SUTTON SM2 5PX,SURREY,ENGLAND

[2] ROYAL MARSDEN HOSP,LONDON,ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1991年 / 63卷 / 02期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/bjc.1991.72

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.

引用

收藏

页码：311 / 313

页数：3

相关论文

共 10 条

[1] THE ANTI-EMETIC POTENTIAL OF THE 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONIST BRL-43694 [J].

BERMUDEZ, J ;

BOYLE, EA ;

MINER, WD ;

SANGER, GJ .

BRITISH JOURNAL OF CANCER, 1988, 58 (05) :644-650

[2] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].

BLACKLEDGE, G ;

LAWTON, F ;

REDMAN, C ;

KELLY, K .

BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653

[3]

BRUCKNER HW, 1987, P AM SOC CLIN ONCOL, V6, P121

[4] PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].

CUNNINGHAM, D ;

POPLE, A ;

FORD, HT ;

HAWTHORN, J ;

GAZET, JC ;

CHALLONER, T ;

COOMBES, RC .

LANCET, 1987, 1 (8548) :1461-1463

[5] TREATMENT OF RELAPSED CARCINOMA OF THE OVARY WITH CISPLATIN OR CARBOPLATIN FOLLOWING INITIAL TREATMENT WITH THESE COMPOUNDS [J].

GORE, ME ;

FRYATT, I ;

WILTSHAW, E ;

DAWSON, T .

GYNECOLOGIC ONCOLOGY, 1990, 36 (02) :207-211

[6] LOW CENTRAL-NERVOUS-SYSTEM PENETRATION OF N-2,N-4,N-6-TRIHYDROXYMETHYL N-2,N-4,N-6-TRIMETHYLMELAMINE (TRIMELAMOL) - A CYTOTOXIC S-TRIAZINE WITH REDUCED NEUROTOXICITY [J].

JUDSON, IR ;

RUTTY, CJ ;

ABEL, G ;

GRAHAM, MA .

BRITISH JOURNAL OF CANCER, 1986, 53 (05) :601-606

[7]

JUDSON IR, 1989, CANCER RES, V49, P5475

[8] INVITRO CYTO-TOXICITY OF THE METHYLMELAMINES [J].

RUTTY, CJ ;

ABEL, G .

CHEMICO-BIOLOGICAL INTERACTIONS, 1980, 29 (02) :235-246

[9] INVITRO STUDIES WITH HEXAMETHYLMELAMINE [J].

RUTTY, CJ ;

CONNORS, TA .

BIOCHEMICAL PHARMACOLOGY, 1977, 26 (24) :2385-2391

[10] THE COMPARATIVE PHARMACOKINETICS OF PENTAMETHYLMELAMINE IN MAN, RAT, AND MOUSE [J].

RUTTY, CJ ;

NEWELL, DR ;

MUINDI, JRF ;

HARRAP, KR .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 8 (01) :105-111